Carregant...
Tipus de document
ArticleVersió
Versió acceptadaData de publicació
Tots els drets reservats
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/135478
Does Progressive Introduction of Benznidazole Reduce the Chance of Adverse Events in the Treatment of Chagas Disease?
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
In this retrospective
cohort study, we aimed to assess whether introducing
benznidazole at escalating doses reduces the probability of
adverse events or treatment discontinuation compared with a
full-dose scheme. We collected data from patients who had
chronic " - " infection and underwent treatment from July 2008
to January 2017 in a referral center in Madrid. Dose was
adjusted to body weight (5 mg/kg/day), with treatment
introduction with full dose or escalating dose according to
local consensus and protocols. Among the 62 patients treated,
benznidazole was introduced at full dose in 28 patients and on
escalating dose in the remaining 34. We found no statistical
differences in the number of adverse events, treatment
discontinuations, days of treatment, or sociodemographic
profiles. There is insufficient evidence to support escalating
dose as a strategy for reducing the adverse effects of
benznidazole. Further research is needed to evaluate this
strategy.
Matèries
Matèries (anglès)
Citació
Col·leccions
Citació
LOSADA, Irene, MADRID PASCUAL, Olaya, HERRERO MARTÍNEZ, Juan maría, PÉREZ AYALA, Ana, LIZASOAIN HERNÁNDEZ, Manuel. Does Progressive Introduction of Benznidazole Reduce the Chance of Adverse Events in the Treatment of Chagas Disease?. _American Journal of Tropical Medicine and Hygiene_. 2019. Vol. 100, núm. 6, pàgs. 1477-1481. [consulta: 24 de gener de 2026]. ISSN: 0002-9637. [Disponible a: https://hdl.handle.net/2445/135478]